Mega Bridge Changes Name, Announces New Strategic Direction

Mega Bridge (OTCQB:MGBR) announced it plans a name for the company to HypeGen, and refocus on developing therapeutic treatment options for Parkinson’s disease.

As quoted in the press release:

To spearhead this new strategic direction, HypGen’s shareholders have elected Dr. McCoy L. Moretz as the new Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chairman of the Board of Directors. Richard Chang has also been appointed to the Board of Directors.

HypGen has been assigned United States Utility Patent Application No. 62/420,177, filed on November 10, 2016 titled “Compositions and Methods of Use of Phorbol Esters for the Treatment of Parkinson’s disease.” The Company plans to conduct clinical studies to assess potential treatment options for Parkinson’s disease based upon this intellectual property platform.

“Our new name better represents our leadership in the field of developing a therapeutic option for the treatment for Parkinson’s disease. With approximately 60,000 Americans diagnosed with Parkinson’s disease each year according to the Parkinson’s Disease Foundation, there is an enormous need for new clinical research into treatment options for this terrible disease. We are delighted to have secured these intellectual property rights, which demonstrate our commitment to rapidly developing therapies that, one day, will hopefully change the lives of patients suffering from Parkinson’s disease,” said Dr. McCoy L. Moretz, Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chairman of the Board of Directors of HypGen.

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.

Biotech

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply